Thurston, Springer, Miller, Herd & Titak, Inc. Moderna, Inc. Transaction History
Thurston, Springer, Miller, Herd & Titak, Inc.
- $283 Million
- Q2 2024
A detailed history of Thurston, Springer, Miller, Herd & Titak, Inc. transactions in Moderna, Inc. stock. As of the latest transaction made, Thurston, Springer, Miller, Herd & Titak, Inc. holds 111 shares of MRNA stock, worth $8,091. This represents 0.0% of its overall portfolio holdings.
Number of Shares
111Holding current value
$8,091% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding MRNA
# of Institutions
1,112Shares Held
241MCall Options Held
9.26MPut Options Held
12.1M-
Baillie Gifford & CO43.4MShares$3.17 Billion4.1% of portfolio
-
Vanguard Group Inc Valley Forge, PA39.6MShares$2.88 Billion0.09% of portfolio
-
Black Rock Inc. New York, NY25.6MShares$1.86 Billion0.07% of portfolio
-
State Street Corp Boston, MA15MShares$1.1 Billion0.08% of portfolio
-
Theleme Partners LLP London, X07.23MShares$527 Million42.67% of portfolio
About Moderna, Inc.
- Ticker MRNA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 391,200,000
- Market Cap $28.5B
- Description
- Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, resp...